Search or Ask Iris
Ctrl+K
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Gaudium IVF and Women Health Limited, incorporated in 2015 and founded by Dr. Manika Khanna, is a prominent provider of In-Vitro Fertilization (IVF) treatments in India. Operating on a hub-and-spoke model, the company has a network of over 30 locations, including 7 main centers and 28 affiliated spokes across multiple states. Gaudium IVF offers a comprehensive suite of fertility services, including IVF, Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), cryopreservation, and advanced genetic testing, alongside specialized care for male infertility and various gynecological conditions.
Feb 20, 2026
Feb 24, 2026
Feb 27, 2026
Mainboard
Upcoming
—
70 Cr
0 Cr
—
—
The net proceeds from the Fresh Issue are proposed to be utilized towards the following objectives:
Funding capital expenditure of ₹50.00 crores towards the establishment of 19 new IVF centers across India in a phased manner to expand the company's geographical presence.
Repayment or pre-payment of certain outstanding loans availed by the company, amounting to ₹20.00 crores, to reduce debt servicing costs and improve the debt-to-equity ratio.
Funding general corporate purposes, which may include strategic initiatives, branding, marketing, and other operational expenses, with the amount not exceeding 25% of the gross proceeds from the Fresh Issue.
—
3.12
21.25%
21.03%
21.34%
—
25.14%
38.29%
—
Growing Demand Base: An expanding patient pool driven by rising infertility rates, delayed marriages, and lifestyle factors, with an estimated 25-30 million infertile couples in India.
Advancing Technology: Adoption of AI-enabled embryo selection, genetic testing, and cryopreservation has improved clinical outcomes and success rates.
Medical Tourism Potential: India is positioned as a global hub for fertility tourism due to affordable treatment costs and experienced specialists.
Scalable Business Models: The hub-and-spoke structure enables efficient expansion into Tier-II and Tier-III cities, widening accessibility.
High Capital Intensity at Scale: Establishing advanced labs and recruiting specialists requires significant upfront investment.
Fragmented Regulation: Despite the ART and Surrogacy Acts, variations in state-level interpretation can create operational inconsistencies.
Social Stigma: Cultural barriers and lack of awareness about fertility treatments persist, particularly in non-metro regions.
Expanding Market Size: The Indian IVF market is projected to reach USD 4.54 billion by 2034, growing at a CAGR of 13.13%.
Insurance and Policy Support: Potential inclusion of fertility treatments in insurance coverage could significantly expand affordability and demand.
Tier-II and Tier-III Penetration: Untapped demand in smaller cities offers significant growth headroom for expansion.
Fertility Preservation: Rising awareness of egg freezing and oncofertility creates new service lines and revenue streams.
Regulatory Tightening: Future restrictions on ART procedures, donor programs, or surrogacy frameworks may impact operational flexibility.
Economic Sensitivity: As a discretionary expense not always covered by insurance, demand for IVF treatments is sensitive to economic slowdowns.
Competition: Increasing entry of large hospital chains and international collaborations may intensify pricing pressure and reduce margins.
Ethical and Legal Scrutiny: Patient rights, consent, and ethical standards are under heightened scrutiny, necessitating continuous compliance investment.
Gaudium IVF and Women Health Limited, incorporated in 2015 and founded by Dr. Manika Khanna, is a prominent provider of In-Vitro Fertilization (IVF) treatments in India. Operating on a hub-and-spoke model, the company has a network of over 30 locations, including 7 main centers and 28 affiliated spokes across multiple states. Gaudium IVF offers a comprehensive suite of fertility services, including IVF, Intracytoplasmic Sperm Injection (ICSI), Intrauterine Insemination (IUI), cryopreservation, and advanced genetic testing, alongside specialized care for male infertility and various gynecological conditions.
The Gaudium IVF & Women Health Ltd. IPO is scheduled to open for subscription on Feb 20, 2026 and close on Feb 24, 2026. Investors can apply for shares during this period through eligible platforms.
The price band for the Gaudium IVF & Women Health Ltd. IPO is yet to be announced. Investors can place bids within this range once the issue opens.
The minimum lot size for the Gaudium IVF & Women Health Ltd. IPO is yet to be announced shares. The minimum investment amount will be known once the price band is finalized.
The total issue size of the Gaudium IVF & Women Health Ltd. IPO is will be disclosed closer to the issue opening. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Gaudium IVF & Women Health Ltd. IPO has been subscribed data will be available once the issue opens. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Gaudium IVF & Women Health Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Gaudium IVF & Women Health Ltd. are expected to list on stock exchanges on Feb 27, 2026, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Gaudium IVF & Women Health Ltd. IPO are proposed to be used for The net proceeds from the Fresh Issue are proposed to be utilized towards the following objectives:, Funding capital expenditure of ₹50.00 crores towards the establishment of 19 new IVF centers across India in a phased manner to expand the company's geographical presence., Repayment or pre-payment of certain outstanding loans availed by the company, amounting to ₹20.00 crores, to reduce debt servicing costs and improve the debt-to-equity ratio., Funding general corporate purposes, which may include strategic initiatives, branding, marketing, and other operational expenses, with the amount not exceeding 25% of the gross proceeds from the Fresh Issue.
Before applying for the Gaudium IVF & Women Health Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
